[1]
|
Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clini-cians, 73, 17-48. https://doi.org/10.3322/caac.21763
|
[2]
|
Concin, N., Matias-Guiu, X., Vergote, I., et al. (2021) ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma. International Journal of Gynecologic Cancer, 31, 12-39.
https://doi.org/10.1136/ijgc-2020-002230
|
[3]
|
Legge, F., Restaino, S., Leone, L., et al. (2020) Clinical Outcome of Recurrent Endometrial Cancer: Analysis of Post- Relapse Survival by Pattern of Recurrence and Secondary Treatment. International Journal of Gynecologic Cancer, 30, 193-200. https://doi.org/10.1136/ijgc-2019-000822
|
[4]
|
Kurra, V., Krajewski, K.M., Jagannathan, J., et al. (2013) Typical and Atypical Metastatic Sites of Recurrent Endometrial Car-cinoma. Cancer Imaging, 13, 113-122. https://doi.org/10.1102/1470-7330.2013.0011
|
[5]
|
Fader, A.N., Roque, D.M., Siegel, E., et al. (2018) Randomized Phase II Trial of Carboplatin-Paclitaxel versus Car-boplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Re-ceptor 2/Neu. Journal of Clinical Oncology, 36, 2044-2051. https://doi.org/10.1200/JCO.2017.76.5966
|
[6]
|
Herrera, F.G., Bourhis, J. and Coukos, G. (2017) Radiotherapy Combination Opportunities Leveraging Immunity for the Next Oncology Practice. CA: A Cancer Journal for Clinicians, 67, 65-85. https://doi.org/10.3322/caac.21358
|
[7]
|
Brooks, E.D. and Chang, J.Y. (2019) Time to Abandon Sin-gle-Site Irradiation for Inducing Abscopal Effects. Nature Reviews Clinical Oncology, 16, 123-135. https://doi.org/10.1038/s41571-018-0119-7
|
[8]
|
Zhao, X., Kong, Y. and Zhang, L. (2020) Anti-PD-1 Immuno-therapy Combined with Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Pa-tient with Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review. Frontiers in Oncology, 10, Article 1625.
https://doi.org/10.3389/fonc.2020.01625
|
[9]
|
He, H., Xu, T., Li, P., et al. (2021) Anti-PD-1 Immunotherapy Com-bined with Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient with Re-fractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review. Frontiers in Oncology, 11, Article 782646.
https://doi.org/10.3389/fonc.2021.782646
|
[10]
|
Xu, H., Hong, Z., Xu, M., et al. (2022) PRaG Therapy of Refrac-tory Metastatic Gastric Cancer: A Case Report. Frontiers in Immunology, 13, Article 926740. https://doi.org/10.3389/fimmu.2022.926740
|
[11]
|
Kong, Y., Zhao, X., Xu, M., et al. (2022) PD-1 Inhibitor Com-bined with Radiotherapy and GM-CSF (PRaG) in Patients with Metastatic Solid Tumors: An Open-Label Phase II Study. Frontiers in Immunology, 13, Article 952066.
https://doi.org/10.3389/fimmu.2022.952066
|
[12]
|
Lin, Q., Sun, X., Zhou, N., et al. (2019) Outcomes of Stereotactic Body Radiotherapy Versus Lobectomy for Stage I Non-Small Cell Lung Cancer: A Propensity Score Matching Analysis. BMC Pulmonary Medicine, 19, Article No. 98.
https://doi.org/10.1186/s12890-019-0858-y
|
[13]
|
Kimura, T., Fujiwara, T., Kameoka, T., Adachi, Y. and Kariya, S. (2022) Stereotactic Body Radiation Therapy for Metastatic Lung Metastases. Japanese Journal of Radiology, 40, 995-1005.
https://doi.org/10.1007/s11604-022-01323-9
|
[14]
|
Palma, D.A., Olson, R., Harrow, S., et al. (2020) Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. Journal of Clinical Oncology, 38, 2830-2838. https://doi.org/10.1200/JCO.20.00818
|
[15]
|
Nakamura, R., Sugawara, J., Yamaguchi, S., et al. (2020) Stereotactic Body Radiotherapy with a Single Isocentre for Multiple Pulmonary Metastases. BJR|Case Reports, 6, Article ID: 20190121. https://doi.org/10.1259/bjrcr.20190121
|
[16]
|
Feng, L., Ye, T., Zhang, J., et al. (2022) Stereotactic Body Radiotherapy for Lung Metastases in a Patient with Giant Cell Tumor of Bone: A Case Report and Literature Review. Annals of Translational Medicine, 10, Article No. 156.
https://doi.org/10.21037/atm-21-6575
|
[17]
|
Oaknin, A., Gilbert, L., Tinker, A.V., et al. (2022) Safety and Anti-tumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair Deficient/Microsatellite Instability-High (dMMR/MSI-H) or Proficient/ Stable (MMRp/MSS) Endometrial Cancer: Interim Results from GARNET—A Phase I, Single-Arm Study. Journal for Immunotherapy of Cancer, 10, e3777. https://doi.org/10.1136/jitc-2021-003777
|
[18]
|
Wang, D., et al. (2022) Phase 2 Study of Tislelizumab Monotherapy in Previously Treated, Locally Advanced, Unresectable or Metastatic Microsatellite Instability-High/Mismatch Re-pair-Deficient Solid Tumors: Gynecological Cancer Subgroup (127). Journal of Gvnecoloaic Oncoloay, 166, S80-S81. https://doi.org/10.1016/S0090-8258(22)01353-1
|
[19]
|
Makker, V., Rasco, D., Vogelzang, N.J., et al. (2019) Len-vatinib plus Pembrolizumab in Patients with Advanced Endometrial Cancer: An Interim Analysis of a Multicentre, Open-Label, Single-Arm, Phase 2 Trial. The Lancet Oncology, 20, 711-718. https://doi.org/10.1016/S1470-2045(19)30020-8
|
[20]
|
Yonemori, K., Yunokawa, M., Ushijima, K., et al. (2022) Lenvatinib plus Pembrolizumab in Japanese Patients with Endometrial Cancer: Results from Study 309/KEYNOT-775. Cancer Science, 113, 3489-3497.
https://doi.org/10.1111/cas.15436
|
[21]
|
Konstantinopoulos, P.A., Gockley, A.A., Xiong, N., et al. (2022) Evalua-tion of Treatment with Talazoparib and Avelumab in Patients with Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncology, 8, 1317-1322.
https://doi.org/10.1001/jamaoncol.2022.2181
|
[22]
|
Ni, J., Zhou, Y., Wu, L., et al. (2021) Sintilimab, Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony Stimulating Factor as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer: Safety Run-in Results of a Multicenter, Single-Arm, Phase II Trial. Radiation Oncology, 16, Article No. 177.
https://doi.org/10.1186/s13014-021-01905-3
|
[23]
|
Jiao, Y., Cao, F. and Liu, H. (2022) Radiation-Induced Cell Death and Its Mechanisms. Health Physics, 123, 376-386.
https://doi.org/10.1097/HP.0000000000001601
|
[24]
|
Kong, Y., Ma, Y., Zhao, X., et al. (2021) Optimizing the Treatment Schedule of Radiotherapy Combined with Anti- PD-1/PD-L1 Immunotherapy in Metastatic Cancers. Frontiers in Oncology, 11, Article 638873.
https://doi.org/10.3389/fonc.2021.638873
|
[25]
|
Bernstein, M.B., Krishnan, S., Hodge, J.W. and Chang, J.Y. (2016) Immunotherapy and Stereotactic Ablative Radio- therapy (ISABR): A Curative Approach? Nature Reviews Clinical On-cology, 13, 516-524.
https://doi.org/10.1038/nrclinonc.2016.30
|
[26]
|
Breen, W.G., Leventakos, K., Dong, H. and Merrell, K.W. (2020) Radiation and Immunotherapy: Emerging Mechanisms of Synergy. Journal of Thoracic Disease, 12, 7011-7023. https://doi.org/10.21037/jtd-2019-cptn-07
|
[27]
|
Popp, I., Grosu, A.L., Niedermann, G. and Duda, D.G. (2016) Immune Modulation by Hypofractionated Stereotactic Radiation Therapy: Therapeutic Implications. Radiotherapy and Oncology, 120, 185-194.
https://doi.org/10.1016/j.radonc.2016.07.013
|
[28]
|
Golden, E.B., Marciscano, A.E. and Formenti, S.C. (2020) Ra-diation Therapy and the in Situ Vaccination Approach. International Journal of Radiation Oncology, Biology, Physics, 108, 891-898.
https://doi.org/10.1016/j.ijrobp.2020.08.023
|
[29]
|
Turgeon, G.-A., Weickhardt, A., Azad, A.A., Solomon, B. and Siva, S. (2019) Radiotherapy and Immunotherapy: A Synergistic Effect in Cancer Care. Medical Journal of Australia, 210, 47-53. https://doi.org/10.5694/mja2.12046
|
[30]
|
Mayoux, M., Roller, A., Pulko, V., et al. (2020) Dendritic Cells Dictate Responses to PD-L1 Blockade Cancer Immunotherapy. Science Translational Medicine, 12, eaav7431. https://doi.org/10.1126/scitranslmed.aav7431
|
[31]
|
Lee, A. and Keam, S.J. (2020) Tislelizumab: First Approval. Drugs, 80, 617-624.
https://doi.org/10.1007/s40265-020-01286-z
|
[32]
|
Kwek, S.S., Kahn, J., Greaney, S.K., et al. (2016) GM-CSF and Ipilimumab Therapy in Metastatic Melanoma: Clinical Outcomes and Immunologic Responses. OncoImmunology, 5, e1101204.
https://doi.org/10.1080/2162402X.2015.1101204
|
[33]
|
Liu, M., Cai, X. and Zeng, Y. (2019) EP1.04-28 The Ab-scopal Effects of the Combination of Radiotherapy and GM-CSF for Patients with Metastatic Thoracic Cancers. Journal of Thoracic Oncology, 14, S980.
https://doi.org/10.1016/j.jtho.2019.08.2153
|
[34]
|
Chen, Y., Gao, M., Huang, Z., Yu, J. and Meng, X. (2020) SBRT Combined with PD-1/PD-L1 Inhibitors in NSCLC Treatment: A Focus on the Mechanisms, Advances, and Future Chal-lenges. Journal of Hematology & Oncology, 13, Article No. 105. https://doi.org/10.1186/s13045-020-00940-z
|
[35]
|
Bezjak, A., Paulus, R., Gaspar, L.E., et al. (2019) Safety and Ef-ficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. Journal of Clinical Oncology, 37, 1316-1325. https://doi.org/10.1200/JCO.18.00622
|
[36]
|
Kong, F.S., Moiseenko, V., Zhao, J., et al. (2021) Organs at Risk Con-siderations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma? International Journal of Radiation Oncology, Biology, Physics, 110, 172-187. https://doi.org/10.1016/j.ijrobp.2018.11.028
|